Trial ID,NCT ID,Trial Title,Trial Phase,Therapeutic Area,Disease,Trial Status,Sponsor,Start Date,End Date,Patient Segment,Countries
421482,NCT05170204,"A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer",I,Infectious Disease,Hepatitis B & C,Planned,Roche {F. Hoffmann-La Roche},16-05-2022,05-10-2027,Adenocarcinoma; ALK; Large Cell; Second line; Stage III,"Australia; Belgium; Hong Kong, S.A.R., China; Norway; South Korea; Spain; Sweden; Turkey; United Kingdom; United States"
416559,NCT05089734,"Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy",I,Neurology,Parkinson’s Disease,Open,Gilead Sciences,17-11-2021,20-01-2024,ALK; EGFR; Second line; Stage III; Stage IV,Puerto Rico; United States
410354,NCT04988295,"A Phase III, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",IV,Neurology,Epilepsy,Open,"Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD {Johnson & Johnson/Janssen-Cilag/Janssen Research Foundation}}
Fisher Clinical Services",17-11-2021,07-08-2026,Adenocarcinoma; EGFR; Large Cell; Maintenance/Consolidation; Second line; Stage III; Stage IV,"Argentina; Belgium; Brazil; Bulgaria; Canada; China; Czech Republic; Denmark; France; Germany; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; Poland; Portugal; Puerto Rico; Russia; South Korea; Spain; Sweden; Taiwan, China; Turkey; United Kingdom; United States"
406638,NCT04928846,"A Phase III Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",III,Cardiovascular,Stroke,Planned,AbbVie,01-06-2022,08-02-2024,Adenocarcinoma; ALK; EGFR; Large Cell; Second line; Stage III; Stage IV,"Argentina; Austria; Belgium; China; Czech Republic; France; Germany; Greece; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Romania; Slovakia; South Africa; South Korea; Sweden; Taiwan, China; Turkey; Ukraine; United States"
406212,NCT04921358,A Randomized Phase III Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody,II,Cardiovascular,Coronary Artery Disease,Open,BeiGene/BeiGene (Shanghai) Biomedical Technology Co.,06-07-2021,14-04-2023,Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line,Australia; China
400139,NCT04819100,LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase III Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC,III,Gastroenterology,Irritable Bowel Syndrome (IBS),Open,Eli Lilly/Loxo Oncology,20-12-2021,13-12-2025,Adjuvant; Stage I; Stage II; Stage III,"Australia; Austria; Belgium; Brazil; Canada; China; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; India; Israel; Italy; Japan; Mexico; Netherlands; Poland; Puerto Rico; Romania; Russia; Singapore; South Korea; Spain; Sweden; Taiwan, China; Turkey; Ukraine; United Kingdom; United States"
400070,NCT04816214,"A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior 1st / 2nd Generation EGFR-TKI or Osimertinib Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)",II,Cardiovascular,Hypertension,Open,Novartis,22-09-2021,15-12-2025,EGFR; Second line; Stage III; Stage IV,"Argentina; Bulgaria; Chile; China; Colombia; Croatia; France; Germany; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Lithuania; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Russia; Serbia; Singapore; Slovenia; South Korea; Spain; Taiwan, China; Thailand; United Kingdom; United States; Vietnam"
397331,NCT04765059,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (COMPEL)",I,Cardiovascular,Coronary Artery Disease,Open,AstraZeneca,12-09-2021,06-10-2025,Adenocarcinoma; EGFR; Large Cell; Maintenance/Consolidation; Second line; Stage III; Stage IV,Austria; China; Germany; Israel; Italy; Spain; United States
392960,NCT04685135,A Randomized Phase III Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,I,Oncology,Lung Cancer,Open,Mirati Therapeutics {MethylGene},29-01-2021,27-11-2024,KRAS; Second line; Stage IV,"Australia; Austria; Belgium; Canada; Czech Republic; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Ireland; Italy; Netherlands; Poland; Portugal; Puerto Rico; Romania; Russia; Singapore; South Korea; Spain; Switzerland; United Kingdom; United States"
391116,NCT04656652,Phase III Randomized Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01),I,Oncology,Lung Cancer,Open,"AstraZeneca
Daiichi Sankyo",21-12-2020,18-05-2024,Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Argentina; Australia; Belgium; Brazil; Canada; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Poland; Puerto Rico; Romania; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan, China; United Kingdom; United States"
390177,NCT04642469,"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy",I,Infectious Disease,Hepatitis B & C,Open,AstraZeneca,30-11-2020,27-05-2024,Adjuvant; Neoadjuvant; Stage II; Stage III,"Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Russia; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Turkey; United Kingdom; United States; Vietnam"
386856,NCT04585490,Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC,II,Neurology,Alzheimer's Disease,Open,"AstraZeneca
Stanford University Medical Center",25-08-2021,13-11-2026,Maintenance/Consolidation; Second line; Squamous Cell; Stage III,United States
377964,NCT04447118,"A Phase III, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy",IV,Gastroenterology,Irritable Bowel Syndrome (IBS),Open,"Jiangsu Hengrui Pharmaceuticals Co. {Jiangsu Hengrui Medicine}/Shanghai Hengrui Pharmaceutical {Shanghai Hengrui Pharmaceutical (Jiangsu Hengrui Medicine, HKG Science & Tech. JV)}",11-09-2020,05-09-2024,Adenocarcinoma; HER2 positive; Large Cell; Second line; Stage III; Stage IV,"Australia; Belgium; China; France; Germany; Italy; Poland; Russia; South Korea; Spain; Taiwan, China; Turkey; United States"
376846,NCT04427072,"A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METdeltaex14).",IV,Gastroenterology,"Inflammatory Bowel Disease (Crohn’s, Ulcerative Colitis)",Open,Novartis,25-09-2020,03-05-2022,Second line; Stage III; Stage IV; Third line,Australia; Belgium; Brazil; Bulgaria; France; Germany; Hungary; India; Israel; Italy; Lithuania; Malaysia; Netherlands; Portugal; Russia; South Africa; South Korea; Spain; Thailand; Vietnam
374298,NCT04385368,"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (Mermaid-1)",IV,Neurology,Parkinson’s Disease,Open,AstraZeneca,17-07-2020,21-11-2022,Adjuvant; Stage II; Stage III,"Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Czech Republic; Denmark; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; India; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Russia; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan, China; Thailand; Turkey; United Kingdom; United States; Vietnam"
373954,NCT04379635,"A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizumab or Placebo in Resectable Stage II or IIIA Non-Small Cell Lung Cancer",III,Oncology,Breast Cancer,Open,BeiGene,29-05-2020,22-11-2024,Adjuvant; Neoadjuvant; Stage II; Stage III,China
372238,NCT04351555,"A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer",IV,Oncology,Colorectal Cancer,Open,AstraZeneca,05-11-2020,24-10-2025,Adenocarcinoma; Adjuvant; EGFR; Large Cell; Neoadjuvant; Stage II; Stage III,"Austria; Brazil; Bulgaria; Chile; China; Germany; India; Israel; Italy; Japan; Mexico; Peru; Poland; Russia; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; United Kingdom; United States; Vietnam"
369576,NCT04303780,"A Phase III Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C",IV,Infectious Disease,Tuberculosis,Closed,Amgen,29-05-2020,18-09-2025,KRAS; Second line; Stage III; Stage IV; Third line,"Australia; Belgium; Brazil; Canada; China; Denmark; Finland; France; Germany; Greece; Hungary; Italy; Japan; Netherlands; Poland; Portugal; Russia; South Korea; Spain; Sweden; Switzerland; Taiwan, China; United Kingdom; United States"
363903,NCT04471428,"A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy",IV,Neurology,Parkinson’s Disease,Closed,"Exelixis
Takeda
Ipsen
Roche {F. Hoffmann-La Roche}",01-10-2020,22-06-2025,Second line; Stage III; Stage IV; Third line,Australia; Austria; Belgium; France; Germany; Greece; Italy; Japan; Poland; Portugal; Russia; South Korea; Spain; United Kingdom; United States
353670,NCT04025879,"A Phase III, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer.",II,Infectious Disease,Hepatitis B & C,Open,Bristol-Myers Squibb,05-11-2019,07-07-2022,Adjuvant; Neoadjuvant; Stage II; Stage III,"Argentina; Australia; Belgium; Brazil; Canada; China; Czech Republic; France; Germany; Ireland; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Puerto Rico; Romania; Russia; Spain; Taiwan, China; United Kingdom; United States"
348814,NCT03937154,"A Phase III Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",III,Gastroenterology,"Liver Diseases (Cirrhosis, NAFLD)",Open,Amgen,26-02-2020,22-06-2024,Fourth line or greater; Second line; Stage I; Stage II; Stage III; Stage IV; Third line; Thrombocytopenia,Argentina; Austria; Brazil; Bulgaria; Chile; Colombia; Greece; Hungary; Mexico; Peru; Poland; Portugal; Romania; Russia; Spain; Turkey; Ukraine; United States
344390,NCT03976375,"A Phase III, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)",II,Oncology,Leukemia & Lymphoma,Open,"Eisai
Merck & Co./Merck Sharp & Dohme (MSD)",26-06-2019,26-10-2022,Adenocarcinoma; KRAS; Large Cell; Second line; Squamous Cell; Stage IV,Argentina; Australia; Canada; Colombia; France; Germany; Greece; Hungary; Israel; Italy; Japan; Portugal; Puerto Rico; Russia; South Korea; Spain; United Kingdom; United States
343299,,Efficacy and Safety of Intas Denosumab in Comparison with Xgeva in Patients with Solid Tumours with Bone Metastases,III,Gastroenterology,"Liver Diseases (Cirrhosis, NAFLD)",Completed,Intas Pharmaceuticals,11-02-2019,11-10-2022,Bone mets; Line of therapy N/A; Stage IV,India
340378,NCT03800134,"A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)",II,Infectious Disease,Hepatitis B & C,Open,"AstraZeneca {MedImmune}
Catalent Pharma Solutions",06-12-2018,25-11-2023,Adenocarcinoma; Adjuvant; ALK; EGFR; Large Cell; Neoadjuvant; Squamous Cell; Stage II; Stage III,"Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Costa Rica; France; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Peru; Philippines; Poland; Puerto Rico; Romania; Russia; South Korea; Spain; Taiwan, China; Thailand; Ukraine; United States; Vietnam"
338410,NCT03768063,"An Open Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech And/Or  F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study",II,Neurology,Parkinson’s Disease,Open,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}",28-02-2019,01-05-2022,Line of therapy N/A; Stage III; Stage IV,"Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Czech Republic; Denmark; France; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; Israel; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Norway; Poland; Portugal; Romania; Russia; Singapore; Slovakia; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
336795,NCT03743051,"A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",IV,Cardiovascular,Hypertension,Open,Helsinn Healthcare,18-12-2018,15-07-2022,Cachexia; Line of therapy N/A; Stage III; Stage IV,Bulgaria; Hungary; Italy; Russia; Serbia; United States
336794,NCT03743064,"A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",II,Neurology,Alzheimer's Disease,Open,Helsinn Healthcare,18-12-2018,10-07-2023,Cachexia; Line of therapy N/A; Stage III; Stage IV,Australia; Belgium; Croatia; Germany; Poland; Romania; Russia; Ukraine; United States
336742,NCT03906071,A Randomized Phase III Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE,I,Gastroenterology,Irritable Bowel Syndrome (IBS),Open,"Bristol-Myers Squibb
Mirati Therapeutics {MethylGene}",15-07-2019,24-03-2021,Adenocarcinoma; Large Cell; Second line; Stage III; Stage IV; Third line,Belgium; Canada; France; Germany; Hungary; Israel; Italy; Netherlands; Spain; Switzerland; United Kingdom; United States
336387,NCT03735121,"A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",IV,Infectious Disease,Tuberculosis,Open,Roche {F. Hoffmann-La Roche},27-12-2018,29-07-2021,EGFR; Second line; Stage III; Stage IV,Argentina; Brazil; Bulgaria; Chile; China; Costa Rica; France; Greece; Guatemala; Hungary; Italy; Latvia; Mexico; New Zealand; Peru; Poland; Russia; South Africa; South Korea; Spain; Thailand; Turkey; Ukraine; United Kingdom
334578,NCT03706690,"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy",II,Gastroenterology,Irritable Bowel Syndrome (IBS),Open,AstraZeneca {MedImmune},27-11-2018,20-04-2023,ALK; EGFR; Maintenance/Consolidation; Second line; Stage III,"China; Hong Kong, S.A.R., China; India; Mexico; Philippines; Poland; Russia; South Korea; Taiwan, China; Turkey"
332125,NCT03728556,"A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy",IV,Neurology,Multiple Sclerosis,Completed,CStone Pharmaceuticals,26-10-2018,23-07-2022,Maintenance/Consolidation; Squamous Cell; Stage III; Stage IV,China
328695,NCT03596866,A Phase III Randomized Open-label Study of Brigatinib (Alunbrig) Versus Alectinib (Alecensa) in Advanced Anaplastic Lymphoma Kinase-Positive Non Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori),III,Neurology,Parkinson’s Disease,Open,"(Other Industry Sponsor)
Takeda {Ariad}
Takeda/Takeda Pharmaceutical (China) Company",19-04-2019,23-11-2021,ALK; Second line; Stage III; Stage IV; Third line,"Argentina; Austria; Brazil; Canada; Chile; China; Croatia; France; Germany; Greece; Hong Kong, S.A.R., China; Hungary; Italy; Mexico; Romania; Russia; South Korea; Spain; Sweden; Taiwan, China; Thailand; United States"
324107,NCT03521154,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA)",I,Gastroenterology,Irritable Bowel Syndrome (IBS),Open,AstraZeneca,19-07-2018,10-08-2023,Adenocarcinoma; EGFR; Large Cell; Maintenance/Consolidation; Stage III,"Argentina; Brazil; China; Hungary; India; Japan; Malaysia; Mexico; Peru; Russia; South Korea; Spain; Taiwan, China; Thailand; Turkey; United States; Vietnam"
323712,NCT03515837,"A Randomized, Double-Blind, Phase III Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)",IV,Gastroenterology,Irritable Bowel Syndrome (IBS),Closed,Merck & Co./Merck Sharp & Dohme (MSD),29-06-2018,04-10-2020,Adenocarcinoma; EGFR; Large Cell; Maintenance/Consolidation; Second line; Stage IV,"Australia; Brazil; Canada; China; France; Germany; Hong Kong, S.A.R., China; Israel; Italy; Japan; Mexico; South Korea; Spain; Sweden; Taiwan, China; United Kingdom; United States"
321216,NCT03542461,"An Open-label, Randomized Phase III Study of Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy-EDEN trial",I,Cardiovascular,Coronary Artery Disease,Closed,"Bristol-Myers Squibb
(Other Hospital/Academic/Medical Center)
Mipharm
Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) {Italian Oncology Group for Cancer Research}",25-09-2017,28-05-2020,Maintenance/Consolidation; Second line; Squamous Cell; Stage III; Stage IV,Italy
319940,NCT03456076,"A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer",II,Neurology,Multiple Sclerosis,Open,"Roche/Chugai Pharmaceutical
Roche {F. Hoffmann-La Roche}
Excella GmbH",16-08-2018,13-07-2022,Adjuvant; ALK; Stage I; Stage II; Stage III,"Australia; Austria; Bosnia and Herzegovina; China; Denmark; Egypt; France; Germany; Greece; Hungary; Israel; Italy; Japan; Kazakhstan; Latvia; Macedonia; New Zealand; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; Slovenia; South Africa; South Korea; Spain; Taiwan, China; Thailand; Turkey; Ukraine; United Kingdom; United States"
318074,NCT03425643,"A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671).",I,Oncology,Leukemia & Lymphoma,Closed,Merck & Co./Merck Sharp & Dohme (MSD),09-03-2018,03-11-2022,Adjuvant; Neoadjuvant; Stage II; Stage III,"Argentina; Australia; Belgium; Brazil; Canada; China; Estonia; France; Germany; Hungary; Ireland; Italy; Japan; Latvia; Lithuania; Malaysia; Poland; Romania; Russia; South Africa; South Korea; Spain; Taiwan, China; Ukraine; United Kingdom; United States"
315876,NCT03390686,"A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer",III,Neurology,Alzheimer's Disease,Open,Prestige Biopharma,01-07-2019,20-09-2024,Adenocarcinoma; Large Cell; Second line; Stage III; Stage IV,Belarus; Bulgaria; Chile; Croatia; Georgia; Greece; Hungary; India; Latvia; Malaysia; Philippines; Poland; Romania; Russia; Serbia; Slovakia; Thailand; Turkey; Ukraine
312793,NCT03626545,"A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)",II,Neurology,Multiple Sclerosis,Completed,Novartis,23-01-2019,27-03-2022,Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line,"Argentina; Australia; Belgium; Brazil; Canada; Chile; China; Czech Republic; Denmark; France; Germany; Greece; Hungary; Israel; Italy; Japan; Jordan; Lebanon; Luxembourg; Netherlands; Poland; Russia; Singapore; South Korea; Spain; Taiwan, China; United States"
312791,NCT03447769,"A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects with Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)",III,Neurology,Parkinson’s Disease,Open,Novartis,16-03-2018,24-04-2020,Adenocarcinoma; Adjuvant; Large Cell; Squamous Cell; Stage II; Stage III,"Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Costa Rica; Czech Republic; Egypt; France; Georgia; Germany; Greece; Guatemala; Hong Kong, S.A.R., China; Hungary; Iceland; India; Israel; Italy; Japan; Jordan; Lebanon; Malaysia; Mexico; Netherlands; New Zealand; Norway; Oman; Panama; Peru; Philippines; Poland; Portugal; Romania; Russia; Singapore; Slovakia; Slovenia; South Korea; Spain; Switzerland; Taiwan, China; Thailand; Turkey; United Arab Emirates; United Kingdom; United States; Vietnam"
304898,NCT03358875,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen.",III,Gastroenterology,Irritable Bowel Syndrome (IBS),Completed,"Bristol-Myers Squibb/Celgene
BeiGene
BeiGene/BeiGene (Shanghai) Co.
BeiGene/BeiGene USA",30-11-2017,29-12-2020,Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV; Third line,Brazil; Bulgaria; China; Hungary; Latvia; Lithuania; Mexico; New Zealand; Poland; Russia; Slovakia; Turkey
303425,NCT03194893,"A Multicenter, International, Rollover Study of Alectinib in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged during Transfection (RET)-Positive Cancer",IV,Infectious Disease,HIV/AIDS,Closed,Roche {F. Hoffmann-La Roche},05-07-2017,13-02-2019,ALK; Second line; Stage III; Stage IV,"France; Hong Kong, S.A.R., China; Italy; Poland; Russia; South Korea; Spain; Taiwan, China; Turkey; United States"
301480,NCT03150875,"Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase III Study (ORIENT-3)",IV,Neurology,Multiple Sclerosis,Completed,Innovent Biologics (Suzhou) Co.,25-05-2017,22-07-2021,Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage III; Stage IV,China
292865,NCT02998528,"Randomized, Open-Label, Phase III Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC",IV,Infectious Disease,Tuberculosis,Completed,"Bristol-Myers Squibb
Ono Pharmaceutical",13-01-2017,15-07-2020,Adenocarcinoma; ALK; EGFR; Large Cell; Neoadjuvant; Squamous Cell; Stage I; Stage II; Stage III,"Argentina; Brazil; Canada; China; France; Greece; Hungary; Ireland; Italy; Japan; Netherlands; Romania; South Africa; South Korea; Spain; Taiwan, China; Turkey; United Kingdom; United States"
284265,NCT02864251,"Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy",I,Neurology,Multiple Sclerosis,Closed,"Bristol-Myers Squibb
Ono Pharmaceutical",17-03-2017,30-06-2018,EGFR; Second line; Stage III; Stage IV; Third line,"China; France; Hong Kong, S.A.R., China; Japan; Singapore; South Korea; Spain; Taiwan, China; United States"
281363,NCT02813785,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy",I,Cardiovascular,Stroke,Completed,Roche {F. Hoffmann-La Roche},01-07-2016,29-04-2020,EGFR; Second line; Stage III; Stage IV,China; Malaysia; Singapore; South Korea; Thailand
277572,NCT03102606,"A Phase III, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (PROTECTIVE 1).",IV,Oncology,Leukemia & Lymphoma,Completed,"BeyondSpring Pharmaceuticals
Dalian Wanchunbulin Pharmaceuticals
Pharmaceutics International",01-04-2017,21-10-2022,Fourth line or greater; Hormone refractory; Neutropenia; Second line; Stage III; Stage IV; Third line,China; Russia; Ukraine; United States
269945,NCT02973789,"LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage IV Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure",II,Oncology,Breast Cancer,Closed,Novocure,01-12-2016,01-11-2019,Adenocarcinoma; Large Cell; Second line; Squamous Cell; Stage IV,"Austria; Belgium; Bulgaria; Canada; China; Croatia; Czech Republic; France; Germany; Hong Kong, S.A.R., China; Hungary; Italy; Netherlands; Poland; Serbia; Spain; Switzerland; United States"
